Drug intelligence / Profile preview

novel COVID-19 mRNA vaccine

Development stage: Unknown
Lead developer: Abogen Bioscience
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The novel COVID-19 mRNA vaccine is an investigational prophylactic agent developed by Shulan (Hangzhou) Hospital for the prevention of infection by SARS-CoV-2. Utilizing messenger RNA technology, the vaccine encodes the viral spike protein to elicit a protective immune response, including the production of neutralizing antibodies and T-cell activation. It is currently being evaluated in a randomized, blinded, parallel-controlled Phase I clinical trial (ChiCTR2300069133) in China. This study aims to assess the safety, preliminary immunogenicity, and immune persistence of the vaccine in healthy adults aged 18 and older, comparing it against both a placebo and an inactivated COVID-19 vaccine comparator.

Other names: novel COVID-19 mRNA vaccine

Targets

ACE2 (Angiotensin-converting enzyme 2)RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on novel COVID-19 mRNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on novel COVID-19 mRNA vaccine.

Explore the full profile